Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
Expert Rev Cardiovasc Ther
; 3(5): 911-24, 2005 Sep.
Article
en En
| MEDLINE
| ID: mdl-16181035
ABSTRACT
The metabolic syndrome (syndrome X) is a cluster of risk factors and a common cause of cardiovascular disease in humans. Although the underlying mechanism for metabolic syndrome is still poorly understood, recent clinical data and studies with transgenic animals implicate elevated intracellular glucocorticoid tone in the etiology of metabolic syndrome. Development of selective inhibitors of 11beta-hydroxysteroid dehydrogenase (11beta-HSD)-1 and their use in rodent animal disease models encompassing several aspects of metabolic syndrome indicate the possibility of therapeutic intervention. This review will focus on recent advances in our understanding of the role of 11beta-HSD1 in metabolic disorders and other disease processes.
Buscar en Google
Bases de datos:
MEDLINE
Asunto principal:
Síndrome Metabólico
/
11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 1
/
Glucocorticoides
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Expert Rev Cardiovasc Ther
Asunto de la revista:
ANGIOLOGIA
/
CARDIOLOGIA
/
TERAPEUTICA
Año:
2005
Tipo del documento:
Article
País de afiliación:
Estados Unidos